Table 1.
Distribution of biomarkers in the primary tumor and metastatic sites.
| IHC | CD3 IF (%) | CD3 stroma (%) | CD3 IE (%) | CD8 IF (%) | CD8 stroma (%) | PD‐1 IF (%) | PD‐1 stroma (%) | Foxp3 IF (%) | Foxp3 stroma (%) | PD‐L1 tumoral cells (%) | PD‐L1 immune cells (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary tumors | |||||||||||||
| All (N = 74) | IHC 3+ | 11 (14.9) | 15 (20.5) | 14 (19.2) | 0 | 0 | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 33 (44.6) | 42 (57.5) | 26 (35.6) | 6 (8.5) | 8 (11.3) | 2 (2.7) | 1 (1.4) | 3 (4.1) | 11 (14.9) | ≥ 5 | 5 (6.8) | 42 (57.5) | |
| IHC 0+ and 1+ | 41 (55.4) | 31 (42.5) | 47 (64.4) | 65 (91.5) | 63 (88.7) | 71 (97.3) | 73 (98.6) | 71 (95.9) | 63 (85.1) | < 5 | 68 (93.2) | 31 (42.5) | |
| Associated with neoadjuvant metastases (N = 40) | IHC 3+ | 4 (10.0) | 8 (20.0) | 7 (17.5) | 0 | 0 | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 16 (40.0) | 22 (55.0) | 13 (32.5) | 2 (5.3) | 5 (13.2) | 1 (2.5) | 0 | 2 (5.0) | 4 (10.0) | ≥ 5 | 2 (5.1) | 22 (56.4) | |
| IHC 0+ and 1+ | 24 (60.0) | 18 (45.0) | 27 (67.5) | 36 (94.7) | 33 (86.8) | 39 (97.5) | 40 (100) | 38 (95.0) | 36 (90.0) | < 5 | 37 (94.9) | 17 (43.6) | |
| Associated with chemo‐naive metastases (N = 34) | IHC 3+ | 7 (20.6) | 7 (21.2) | 7 (21.2) | 0 | 0 | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 17 (50.0) | 20 (60.6) | 13 (39.4) | 4 (12.1) | 3 (9.1) | 1 (3.0) | 1 (2.9) | 1 (2.9) | 7 (20.6) | ≥ 5 | 3 (8.8) | 20 (58.8) | |
| IHC 0+ and 1+ | 17 (50.0) | 13 (39.4) | 20 (60.6) | 29 (87.9) | 30 (90.9) | 32 (97) | 33 (97.1) | 33 (97.1) | 27 (79.4) | < 5 | 31 (91.2) | 14 (41.2) | |
| Metastases | |||||||||||||
| All (N = 74) | IHC 3+ | 16 (21.9) | 10 (13.5) | 12 (16.4) | 2 (2.8) | 3 (4.2) | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 63 (86.3) | 30 (40.5) | 20 (27.4) | 23 (31.9) | 16 (22.2) | 9 (12.7) | 4 (5.6) | 0 | 4 (5.6) | ≥ 5 | 7 (9.7) | 44 (61.1) | |
| IHC 0+ and 1+ | 10 (13.7) | 44 (59.5) | 53 (72.6) | 49 (68.1) | 56 (77.8) | 62 (87.3) | 67 (94.4) | 72 (100) | 68 (94.4) | < 5 | 65 (90.3) | 28 (38.9) | |
| Neoadjuvant (N = 40) | IHC 3+ | 11 (28.2) | 7 (17.5) | 5 (12.5) | 1 (2.6) | 2 (5.1) | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 32 (82.1) | 19 (47.5) | 8 (20.0) | 16 (41.0) | 10 (25.6) | 6 (15.8) | 3 (7.9) | 0 | 0 | ≥ 5 | 5 (13.2) | 21 (55.3) | |
| IHC 0+ and 1+ | 7 (17.9) | 21 (52.5) | 32 (80.0) | 23 (59.0) | 29 (74.4) | 32 (84.2) | 35 (92.1) | 39 (100) | 39 (100) | < 5 | 33 (86.8) | 17 (44.7) | |
| Chemo‐naive (N = 34) | IHC 3+ | 5 (14.7) | 3 (8.8) | 7 (21.2) | 1 (3.0) | 1 (3.0) | NA | NA | NA | NA | |||
| IHC 2+ and 3+ | 31 (91.2) | 11 (32.4) | 12 (36.4) | 7 (21.2) | 6 (18.2) | 3 (9.1) | 1 (3.0) | 0 | 4 (12.1) | ≥ 5 | 2 (5.9) | 23 (67.6) | |
| IHC 0+ and 1+ | 3 (8.8) | 23 (37.6) | 21 (63.6) | 26 (78.8) | 27 (81.8) | 30 (90.9) | 32 (97.0) | 33 (100) | 29 (87.9) | < 5 | 32 (94.1) | 11 (32.4) | |